Berenberg Bank Reaffirms Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by equities research analysts at Berenberg Bank in a research report issued to clients and investors on Wednesday, Digital Look reports. They presently have a £175 price objective on the biopharmaceutical company’s stock. Berenberg Bank’s target price indicates a potential upside of 44.59% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Citigroup upped their price objective on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Royal Bank Of Canada reiterated an “outperform” rating and issued a £145 price target on shares of AstraZeneca in a research report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 price objective on shares of AstraZeneca in a research report on Tuesday, September 29th. Finally, Jefferies Financial Group restated a “buy” rating and set a £175 price target on shares of AstraZeneca in a report on Wednesday, September 9th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of £153.57.

AstraZeneca Trading Down 0.6%

Shares of LON:AZN opened at £121.03 on Wednesday. The company’s 50-day moving average price is £120.74 and its 200 day moving average price is £132.20. The company has a market cap of £187.71 billion, a PE ratio of 18.12, a P/E/G ratio of 0.86 and a beta of 0.20. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. AstraZeneca has a fifty-two week low of £114.04 and a fifty-two week high of £157.32.

Insiders Place Their Bets

In other AstraZeneca news, insider Michel Demare bought 2,500 shares of the stock in a transaction on Monday, September 14th. The shares were purchased at an average price of £121.21 per share, with a total value of £303,025. 0.15% of the stock is currently owned by insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.